Inactive Instrument

Avanir Pharmaceuticals Inc Share Price

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2014	Otsuka : Japan's Otsuka to buy Avanir for $3.5 billion ahead of patent cliff	RE
2014	NASDAQ OMX : names 14 stocks to test lower fee and rebate programme	RE

Otsuka : Japan's Otsuka to buy Avanir for $3.5 billion ahead of patent cliff	02/14/02	RE
NASDAQ OMX : names 14 stocks to test lower fee and rebate programme	17/14/17	RE
Apple : Nasdaq slumps to worst day since July; S&P 500 dips	16/14/16	RE

Avanir Pharmaceuticals : Announces Appointment of Rohan Palekar as President and Chief Executive Officer	20/16/20	PR
Avanir Pharmaceuticals : Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer’s Disease	10/15/10	PU
Avanir Pharmaceuticals : Announces JAMA Publication of Phase II Study Results Showing AVP-923 Significantly Reduced Agitation in Patients with Alzheimer's Disease	22/15/22	PU
Avanir Pharmaceuticals : Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026	11/15/11	PU
Avanir Pharmaceuticals : Announces New Findings from Dementia/Alzheimer's Disease Cohort of PRISM II Study at Alzheimer's Association International Conference	23/15/23	PU

Apple : Wall Street ouvre en légère hausse	02/14/02
Les valeurs à suivre mardi 2 décembre 2014 à Wall Street	02/14/02
AVANIR PHARMACEUTICALS : cédé au japonais Otsuka Pharmaceutical pour 3,5 milliards de dollars	02/14/02
Les valeurs à suivre sur les marchés américains	02/14/02

Managers	Title	Age	Since
Dan Dalton CMP	Compliance Officer	-	01/16/01
Kelly Parker IRO	Public Communications Contact	-	01/15/01
Aneta Ferguson LAW	General Counsel	-	01/15/01

Members of the board	Title	Age	Since
Donald Hayden CHM	Chairman	68	-
Robert McQuade BRD	Director/Board Member	67	-
Thomas DesRosier BRD	Director/Board Member	69	-

Sector

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.41%	103B
REGENERON PHARMACEUTICALS, INC.	+1.74%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-15.68%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.01%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.28%	13.68B
SAREPTA THERAPEUTICS, INC.	+35.00%	12.17B